Brainsway (BWAY)

• Market cap: $174M
• 1 day: 1.10%
• 5 days: -0.97%
• 1 month: -6.86%
• 3 months: -0.11%
• 6 months: 57.51%
• Year to date: 27.84%
• 1 year: 27.84%
• 5 years: -5.33%
• 10 years: -16.77%

About: BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Employees: 106

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

133% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 6

40% more capital invested

Capital invested by funds: $21.7M [Q2] → $30.4M (+$8.61M) [Q3]

19% more funds holding

Funds holding: 27 [Q2] → 32 (+5) [Q3]

0.9% less ownership

Funds ownership: 10.75% [Q2] → 9.85% (-0.9%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12.50 35% upside
• Avg. target: $14.25 54% upside
• High target: $16 73% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 42% 1-year accuracy 132 / 311 met price target	73% upside $16	Buy Reiterated	23 Dec 2024
Northland Capital Markets Carl Byrnes 100% 1-year accuracy 5 / 5 met price target	35% upside $12.50	Outperform Maintained	3 Oct 2024